Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Analysis of the inheritance pattern of a Chinese family with phaeochromocytomas through whole exome sequencing.

Gene·2013
Same author

Discovery of novel, induced-pocket binding oxazolidinones as potent, selective, and orally bioavailable tankyrase inhibitors.

Journal of medicinal chemistry·2013
Same author

Sequential [3 + 2] and [4 + 2] cycloadditions for stereoselective synthesis of a novel polyheterocyclic scaffold.

ACS combinatorial science·2013
Same author

VEGF-c expression in an in vivo model of orthotopic endometrial cancer and retroperitoneal lymph node metastasis.

Reproductive biology and endocrinology : RB&E·2013
Same author

[Expression of interleukin-6 and its clinicopathological significance in Castleman's disease].

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi·2013
Same author

miR-210 suppresses BNIP3 to protect against the apoptosis of neural progenitor cells.

Stem cell research·2013

Related Experiment Video

Updated: May 12, 2025

A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes
07:59

A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes

Published on: March 25, 2014

14.8K

Statistical Tutorial for Cut-Point Determination in Immunogenicity Studies.

Yulia Mordashova1, Xin Huang2

  • 1AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany.

Pharmaceutical Statistics
|May 9, 2025
PubMed
Summary
This summary is machine-generated.

Assessing drug immunogenicity requires validating Anti-Drug Antibody (ADA) assays. This study provides statistical methods and R code for reliable ADA assay cut-point evaluation, enhancing clinical safety assessments.

Keywords:
ADA assay cut‐point estimationADA assay validationimmunogenicity

More Related Videos

Application of Biochip Microfluidic Technology to Detect Serum Allergen-specific Immunoglobulin E sIgE
07:10

Application of Biochip Microfluidic Technology to Detect Serum Allergen-specific Immunoglobulin E sIgE

Published on: April 21, 2019

16.3K
Characterization of Thymus-dependent and Thymus-independent Immunoglobulin Isotype Responses in Mice Using Enzyme-linked Immunosorbent Assay
06:15

Characterization of Thymus-dependent and Thymus-independent Immunoglobulin Isotype Responses in Mice Using Enzyme-linked Immunosorbent Assay

Published on: September 7, 2018

9.4K

Related Experiment Videos

Last Updated: May 12, 2025

A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes
07:59

A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes

Published on: March 25, 2014

14.8K
Application of Biochip Microfluidic Technology to Detect Serum Allergen-specific Immunoglobulin E sIgE
07:10

Application of Biochip Microfluidic Technology to Detect Serum Allergen-specific Immunoglobulin E sIgE

Published on: April 21, 2019

16.3K
Characterization of Thymus-dependent and Thymus-independent Immunoglobulin Isotype Responses in Mice Using Enzyme-linked Immunosorbent Assay
06:15

Characterization of Thymus-dependent and Thymus-independent Immunoglobulin Isotype Responses in Mice Using Enzyme-linked Immunosorbent Assay

Published on: September 7, 2018

9.4K

Area of Science:

  • Biopharmaceutical Development
  • Immunology
  • Biostatistics

Background:

  • Therapeutic protein administration can trigger immune responses, producing Anti-Drug Antibodies (ADA).
  • ADA can impact drug safety and efficacy, necessitating robust immunogenicity assessment.
  • Current guidance covers assay validation but lacks comprehensive statistical evaluation methods for cut-points.

Purpose of the Study:

  • To provide enhanced statistical considerations for Anti-Drug Antibody (ADA) assay development and validation cut-points.
  • To offer practical R code for implementing key ADA assay validation steps.
  • To improve the rigor and reliability of immunogenicity assessments in clinical studies.

Main Methods:

  • Review of existing regulatory guidance on immunoassay development and validation.
  • Exploration of statistical methods for screening and confirmatory assay cut-point estimation.
  • Development of R code snippets for practical application of statistical methods.

Main Results:

  • Identified a need for more detailed statistical guidance on ADA assay cut-point determination.
  • Presented specific statistical considerations tailored for ADA assay validation.
  • Provided functional R code for implementing statistical evaluations.

Conclusions:

  • Reliable ADA assay validation is crucial for accurate immunogenicity assessment.
  • The provided statistical methods and R code enhance the evaluation of ADA assay cut-points.
  • This resource supports more robust clinical safety evaluations of therapeutic protein products.